Media headlines about Hologic (NASDAQ:HOLX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hologic earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 44.5771381452498 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Analyzing Hologic (HOLX) & Check Cap (CHEK) (americanbankingnews.com)
- Global Gynecologica Market 2018 – Karl StorzGmbH & Co. KG, Hologic, Inc., Boston Scientific Corporation, Stryker … (newmexicocourierexpress.com)
- Hologic, Inc. (HOLX) ended its day with the change of 0.48% (nasdaqfortune.com)
- Hologic, Inc. (NASDAQ: HOLX), Hormel Foods Corporation (NYSE: HRL) – Whirling Stocks: (productioninvestments.com)
- Global Tissue Ablation Products Market 2018 – Cynosure, Elekta, Hologic, Medtronic, Covidien (marketingcorrect.com)
Several analysts recently weighed in on HOLX shares. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price objective on shares of Hologic in a research report on Friday, February 9th. Deutsche Bank downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a report on Friday, January 19th. Canaccord Genuity reissued a “buy” rating and issued a $48.00 target price on shares of Hologic in a research report on Friday, February 9th. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a research report on Tuesday, February 13th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $44.00 price objective on shares of Hologic in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $47.21.
NASDAQ:HOLX traded down $1.02 during mid-day trading on Friday, reaching $36.43. 2,181,431 shares of the company were exchanged, compared to its average volume of 2,562,864. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. Hologic has a 12 month low of $35.33 and a 12 month high of $46.80. The firm has a market cap of $10,356.01, a P/E ratio of 17.95, a P/E/G ratio of 1.69 and a beta of 0.85.
Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.05. The company had revenue of $791.10 million for the quarter, compared to the consensus estimate of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company’s revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.52 EPS. equities analysts predict that Hologic will post 2.25 earnings per share for the current fiscal year.
In other Hologic news, Director Namal Nawana purchased 6,600 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was bought at an average cost of $37.88 per share, with a total value of $250,008.00. Following the purchase, the director now directly owns 6,954 shares of the company’s stock, valued at $263,417.52. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Allison P. Bebo sold 7,000 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $38.75, for a total transaction of $271,250.00. The disclosure for this sale can be found here. Company insiders own 0.79% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Hologic (HOLX) Receiving Somewhat Favorable Press Coverage, Accern Reports” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-hologic-holx-share-price.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.